HDAC1,2抑制联合多柔比星损害Mre11依赖性DNA修复及DISC,克服费城染色体阳性B细胞前体急性淋巴细胞白血病中BCR-ABL1驱动的双链断裂修复
费城染色体阳性B细胞前体急性淋巴细胞白血病(Ph+ B-ALL)表达BCR-ABL1,预后差且高度依赖双链断裂(DSB)修复。本研究报道首创HDAC1,2选择性抑制剂与多柔比星通过共同及不同机制损害DSB修复网络,包括影响Mre11-Rad51-DNA连接酶1轴及DISC,并在难治性Ph+ B-ALL患者来源异种移植小鼠模型中降低白血病负荷。
要点
- HDAC1,2选择性抑制剂与多柔比星单独或联合损害Ph+ B-ALL细胞中Mre11-Rad51-DNA连接酶1轴。
- HDAC1,2抑制剂改变核小体占据影响染色质结构,多柔比星无此作用。
- 两药分别通过染色质重塑依赖和非依赖机制干扰DISC。
核心结论
- HDAC1,2选择性抑制可克服DSB修复依赖性,为Ph+ B细胞前体ALL提供有效治疗选择。
研究设计与样本
- 机制与临床前研究,使用Ph+ B细胞前体ALL细胞及难治性患者来源异种移植小鼠模型。
主要发现
- HDAC1,2抑制剂而非多柔比星通过MNase-Seq显示改变核小体占据影响染色质结构。
- 定量染色质蛋白质组质谱及功能实验显示HDAC1,2抑制剂和多柔比星单独或联合损害Mre11-Rad51-DNA连接酶1轴。
- HDAC1,2抑制剂和多柔比星分别通过染色质重塑依赖和非依赖机制干扰DISC或顺式转录沉默程序。
- HDAC1,2抑制剂单用或联合多柔比星在难治性Ph+ B细胞前体ALL PDX小鼠模型中降低白血病负荷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL) expressing BCR-ABL1 oncoprotein is a major subclass of ALL with poor prognosis. BCR-ABL1-expressing leukemic cells are highly dependent on double-strand break (DSB) repair signals for their survival. Here we report that a first-in-class HDAC1,2 selective inhibitor and doxorubicin (a hyper-CVAD chemotherapy regimen component) impair DSB repair networks in Ph+ B-cell precursor ALL cells using common as well as distinct mechanisms. The HDAC1,2 inhibitor but not doxorubicin alters nucleosomal occupancy to impact chromatin structure, as revealed by MNase-Seq. Quantitative mass spectrometry of the chromatin proteome along with functional assays showed that the HDAC1,2 inhibitor and doxorubicin either alone or in combination impair the central hub of DNA repair, the Mre11-Rad51-DNA ligase 1 axis, involved in BCR-ABL1-specific DSB repair signaling in Ph+ B-cell precursor ALL cells. HDAC1,2 inhibitor and doxorubicin interfere with DISC (DNA damage-induced transcriptional silencing in cis)) or transcriptional silencing program in cis around DSB sites via chromatin remodeler-dependent and -independent mechanisms, respectively, to further impair DSB repair. HDAC1,2 inhibitor either alone or when combined with doxorubicin decreases leukemia burden in vivo in refractory Ph+ B-cell precursor ALL patient-derived xenograft mouse models. Overall, our novel mechanistic and preclinical studies together demonstrate that HDAC1,2 selective inhibition can overcome DSB repair 'addiction' and provide an effective therapeutic option for Ph+ B-cell precursor ALL.
引用
- Tharkar-Promod S, Johnson DP, Bennett SE, et al. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. 2017. PMID: 28579617. doi:10.1038/leu.2017.174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。